C-Ray Therapeutics Unveils Promising Data for Cancer Therapy in Barcelona

C-Ray Therapeutics (Shanghai) Co., Ltd. presented groundbreaking clinical results for its innovative treatment, 225Ac-PSMA-CY313, during the 2025 Annual Congress of the European Association of Nuclear Medicine (EANM 2025) held in Barcelona, Spain. The company, which focuses on developing targeted radiopharmaceuticals, showcased data indicating the therapy’s potential in treating metastatic castration-resistant prostate cancer (mCRPC). Highlighted in two top-rated oral presentations, these findings underscore a significant step forward for C-Ray in the competitive field of targeted alpha therapies.

One presentation, titled “Feasibility study of 225Ac-PSMA-CY313 dosimetry in mCRPC patients using SPECT,” detailed the progress made in evaluating internal radiation doses for patients treated with 225Ac-PSMA-CY313. The study successfully established a quantitative dosimetry approach using SPECT/CT, validating that tumors, particularly soft tissue lesions, received high absorbed doses while critical organs like the kidneys and liver remained within safe exposure limits. Notably, no severe adverse events (SAEs) or grade ≥3 toxicities were reported during treatment, supporting a favorable therapeutic window.

The second presentation, “Evaluation of the safety and efficacy of 225Ac-PSMA-CY313 in metastatic castration-resistant prostate cancer: preliminary results,” reported outcomes from 13 patients undergoing treatment with the novel therapy. Remarkably, all patients achieved reductions in prostate-specific antigen (PSA) levels, with 81.8% of patients demonstrating a PSA50 response, defined as a ≥50% decline. Among evaluable patients, the objective response rate (ORR) reached 60%. Most reported adverse events were classified as grade 1–2, with xerostomia (dry mouth) being the most common side effect, affecting 11 of 13 patients (84.6%).

“Presenting these results on such a globally recognized stage as EANM represents a significant milestone for C-Ray,” stated the Chief Medical Officer of C-Ray Shanghai. “There are only a few teams worldwide that have successfully advanced an alpha-emitting radiopharmaceutical into clinical development. Not only have we developed 225Ac-PSMA-CY313, but we have also generated robust early clinical data from more than a dozen patients. This underscores our strong capabilities and commitment in both radiopharmaceutical R&D and clinical translation.”

About C-Ray Therapeutics

C-Ray Therapeutics (Shanghai) is a biotechnology company dedicated to discovering and developing innovative targeted radiopharmaceuticals. Based in Shanghai, the company is advancing its pipeline from early-stage discovery through clinical development while building proprietary conjugation and linker platforms.

To foster innovation in ligands, linkers, and conjugation technologies, C-Ray actively seeks global partnerships. The company collaborates closely with its affiliated entity, C-Ray Therapeutics (Chengdu) Co., Ltd., to ensure seamless translation from early research to clinical development. This strategic partnership leverages C-Ray Chengdu’s specialized CRDMO services, covering radiochemistry process development, quality research, preclinical evaluation, IND-enabling support, clinical supply, and commercial-scale manufacturing with secure logistics. This integrated model allows C-Ray Shanghai to maintain its focus on innovation and the expansion of its core competencies.

The recent presentations at EANM 2025 not only highlight C-Ray’s advancements in cancer treatment but also reinforce its position as a leader in the field of targeted radiopharmaceuticals.